Nephrogenic Systemic Fibrosis: A Report of 29 Cases

The strong association between nephrogenic systemic fibrosis and gadolinium-based contrast administration is confirmed, and several of the authors' patients received standard doses of gadolinum, and two had transient acute renal failure before diagnosis.

Abstract

We confirm the strong association between nephrogenic systemic fibrosis and gadolinium-based contrast administration. Although the use of high doses of gadolinium and the occurrence of chronic renal failure have been implicated in other reports, several of our patients received standard doses of gadolinium, and two had transient acute renal failure before diagnosis. Most patients had mild or moderate symptoms. Nephrogenic systemic fibrosis developed in 2.9% of patients undergoing long-term dialysis who received gadolinium-based contrast material but in none of the long-term dialysis patients who did not receive gadolinium-based contrast material.